Aura Biosciences Inc (AURA)

10:58 AM

When (AURA) Moves Investors should Listen - Stock Traders Daily

10:58 AM

Nov 18, 2024

Aura Biosciences' chief medical officer sells $110,663 in stock - Investing.com

Nov 18, 2024

Nov 18, 2024

HC Wainwright Forecasts Higher Earnings for Aura Biosciences - Defense World

Nov 18, 2024

Nov 18, 2024

HC Wainwright Has Bullish Forecast for AURA FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 17, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 17, 2024

Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 17, 2024

Nov 16, 2024

What is Leerink Partnrs’ Estimate for AURA FY2024 Earnings? - Defense World

Nov 16, 2024

Nov 15, 2024

Leerink Partnrs Has Strong Forecast for AURA FY2024 Earnings - MarketBeat

Nov 15, 2024

Nov 15, 2024

Citadel Advisors LLC Reduces Stake in Aura Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World

Nov 15, 2024

Nov 14, 2024

HC Wainwright Reaffirms Buy Rating for Aura Biosciences (NASDAQ:AURA) - MarketBeat

Nov 14, 2024

Nov 13, 2024

Aura Biosciences Reports Q3 Financial Results - TipRanks

Nov 13, 2024

Nov 13, 2024

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - MSN

Nov 13, 2024

Nov 12, 2024

Aura Biosciences : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K - Marketscreener.com

Nov 12, 2024

Nov 12, 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Nov 12, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 12, 2024

Oct 31, 2024

One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance

Oct 31, 2024

Oct 30, 2024

Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat

Oct 30, 2024

Oct 30, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat

Oct 30, 2024

Oct 29, 2024

Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia

Oct 29, 2024

Oct 29, 2024

Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com

Oct 29, 2024

Oct 29, 2024

Aura Biosciences VP sells shares worth $5,938 - Investing.com

Oct 29, 2024

Oct 23, 2024

Don't Ignore The Insider Selling In Aura Biosciences - Simply Wall St

Oct 23, 2024

Oct 23, 2024

Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling - Defense World

Oct 23, 2024

Oct 22, 2024

Aura Biosciences CFO Julie Feder sells shares worth $302,361 - Investing.com India

Oct 22, 2024

Oct 22, 2024

Aura Biosciences (NASDAQ:AURA) Trading Down 4.9% on Insider Selling - MarketBeat

Oct 22, 2024

Oct 21, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock - MarketBeat

Oct 21, 2024

Oct 21, 2024

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha

Oct 21, 2024

Oct 21, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Analysts - Defense World

Oct 21, 2024

Oct 20, 2024

Long Term Trading Analysis for (AURA) - Stock Traders Daily

Oct 20, 2024

Oct 20, 2024

Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright - Defense World

Oct 20, 2024

Oct 19, 2024

Aura Biosciences stock hits 52-week high at $12.38 By Investing.com - Investing.com Australia

Oct 19, 2024

Oct 19, 2024

Aura Biosciences CEO sells $300,838 in stock By Investing.com - Investing.com Australia

Oct 19, 2024

Oct 19, 2024

Aura Biosciences reports promising early trial results - Investing.com India

Oct 19, 2024

Oct 18, 2024

Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock - MarketBeat

Oct 18, 2024

Oct 18, 2024

Aura Biosciences CEO sells $300,838 in stock - Investing.com

Oct 18, 2024

Oct 18, 2024

Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Oct 18, 2024

Oct 18, 2024

Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data - MarketWatch

Oct 18, 2024

Oct 18, 2024

Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade - MarketBeat

Oct 18, 2024

Oct 18, 2024

Aura Biosciences stock hits 52-week high at $12.38 - Investing.com

Oct 18, 2024

Oct 18, 2024

Aura Biosciences stock maintains Buy rating on promising trial results By Investing.com - Investing.com Canada

Oct 18, 2024

Oct 18, 2024

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Benzinga

Oct 18, 2024

Oct 18, 2024

Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at Scotiabank - MarketBeat

Oct 18, 2024

Oct 18, 2024

Aura Biosciences stock price target up 5%, H.C. Wainwright rates Buy after virtual oncology event - Investing.com Canada

Oct 18, 2024

Oct 18, 2024

Aura Biosciences Shares Surge After-Hour On Positive Clinical Trial Results - Stocks Telegraph

Oct 18, 2024

Oct 17, 2024

Multiple Clinical Complete Responses Demonstrated Following - GlobeNewswire

Oct 17, 2024

Oct 17, 2024

Aura Biosciences Reports Positive Phase 1 Trial Results - TipRanks

Oct 17, 2024

Oct 17, 2024

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial - The Manila Times

Oct 17, 2024

Oct 17, 2024

Aura Biosciences reports promising early trial results By Investing.com - Investing.com UK

Oct 17, 2024